Roquefort Therapeutics (LON:COIL) Posts Earnings Results

Roquefort Therapeutics (LON:COIL) issued its quarterly earnings results on Wednesday. The company reported GBX (2.19) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 18.30%.

Roquefort Therapeutics Stock Down 9.0%

COIL stock opened at GBX 7.10 on Friday. Roquefort Therapeutics has a 52 week low of GBX 6.75 and a 52 week high of GBX 10. The business has a 50-day simple moving average of GBX 9.01 and a 200 day simple moving average of GBX 12.64. The company has a quick ratio of 3.07, a current ratio of 2.80 and a debt-to-equity ratio of 8.07. The company has a market cap of £30.24 million, a PE ratio of -1.13 and a beta of 0.05.

Roquefort Therapeutics Company Profile

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.